Archives
-
Bismuth Subsalicylate: Assay Logic Beyond GI Models
2026-09-25
Bismuth Subsalicylate is a research compound for gastrointestinal disorder and inflammation pathway studies. This article explains how to separate compound handling, pathway-level evidence, and assay readouts—using annexin V methodology to clarify what a biological assay can and cannot establish.
-
SMYD2 Inhibition Limits Cisplatin-Related Renal Fibrosis
2026-09-25
A 2023 study links increased SMYD2 to cisplatin-induced kidney injury and reports that pharmacological inhibition reduces renal fibrosis, epithelial transition and inflammatory signaling. The findings position SMYD2 as a candidate regulator of injury responses, while leaving questions about mechanism, dosing and relevance beyond this preclinical model.
-
METTL17 Links Mitochondrial Translation to CRC Ferroptosis
2026-09-24
The study identifies METTL17 as a mitochondrial regulator that helps colorectal cancer cells resist ferroptosis by maintaining mitochondrial RNA methylation, protein translation, and metabolic function. Its results connect this mitochondrial program to tumor growth in cellular and animal models, while suggesting that METTL17 suppression could increase sensitivity to ferroptotic stress.
-
Bestatin Hydrochloride: Mechanistic Research Workflows
2026-09-24
Use Bestatin hydrochloride to test how aminopeptidase activity shapes peptide signaling, endothelial behavior, and tumor-related phenotypes. This guide connects a classic neuronal experiment with practical cell-based workflows, controls, and troubleshooting—while keeping cross-model conclusions appropriately bounded.
-
Doxycycline Hyclate: MMP Biology to BBB Strategy
2026-09-23
A mechanistic and translational framework for using doxycycline hyclate to investigate MMP-associated blood–brain barrier disruption, with evidence-aware experimental guidance and clear limits on interpretation.
-
S-Adenosylhomocysteine in Cell Assays
2026-09-23
Learn how S-Adenosylhomocysteine (SKU B6123) can support controlled methyltransferase inhibition, SAM/SAH ratio modulation, and mechanistic interpretation in viability, proliferation, and differentiation workflows. The article connects product handling data with practical assay design and published neural-cell evidence.
-
Protease Inhibitor Cocktail: MS Workflow
2026-09-22
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue extraction with an AEBSF-free formulation intended for mass spectrometry workflows. It should be validated for each sample matrix, supplemented separately when metalloproteinase control is required, and not treated as a complete phosphatase-inhibitor system.
-
Protecting DFCP1–ATGL Lipolysis Evidence
2026-09-22
The DFCP1–ATGL axis illustrates why translational lipid-droplet research depends on more than detecting protein abundance. Because extraction can disrupt complexes, erase phosphostates, or permit proteolysis, sample preservation becomes part of the mechanistic experiment. This thought-leadership guide connects the reference study’s findings on DFCP1-regulated ATGL residence time with practical strategies for cell lysates, tissue extracts, co-immunoprecipitation, imaging, and kinase workflows. It also explains where the Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) adds value—and where EDTA requires deliberate validation.
-
Protease Control for Translational Proteomics
2026-09-21
Protein integrity is a strategic variable in translational research, not merely a sample-preparation detail. This thought-leadership guide connects pH-dependent viral structural biology with practical protease inhibition in protein extraction and shows how APExBIO’s MS-compatible formulation can strengthen proteomic, biochemical, and mechanistic workflows.
-
ANKFY1 Links Endosomes to Phagophore Expansion
2026-09-21
The 2024 Cell Discovery study identifies ANKFY1 as an endosome-localized ATG2A-binding protein that connects PI3P-rich endosomes with growing phagophores. Its results support endosomes as an additional lipid source for autophagosome biogenesis and clarify how membrane contact-site proteins may coordinate lipid transfer during autophagy.
-
Machine Learning for Senolytic Discovery
2026-09-20
The reference study demonstrates that machine-learning models trained only on published screening data can identify senolytic candidates despite small, heterogeneous datasets. Experimental validation of ginkgetin, periplocin, and oleandrin shows how literature mining can reduce early-stage screening costs while preserving the need for context-specific selectivity testing.
-
JC-1 Mitochondrial Membrane Potential Assay Kit Workflow
2026-09-19
Turn mitochondrial depolarization into a quantitative red-to-green signal for apoptosis assay development, drug screening, and mitochondrial function analysis. This workflow connects the JC-1 readout to hypoxia-activated cancer therapy research while emphasizing controls, normalization, and troubleshooting.
-
DFCP1 Controls ATGL-Driven Lipid Droplet Lipolysis
2026-09-18
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of starvation-induced lipid droplet catabolism. Its central mechanistic finding is that DFCP1 recruits ATGL to lipid droplets while limiting ATGL exchange, thereby restraining lipolysis rather than simply changing droplet abundance.
-
Palomid 529 (P529) for PI3K/Akt/mTOR Studies
2026-09-18
Palomid 529 (P529) enables pathway-focused cancer research by simultaneously interrogating mTORC1 and mTORC2, with applications spanning ESCC resistance, tumor angiogenesis inhibition, and radiotherapy enhancement. This guide translates the RCN2–PPP2CA–PI3K-AKT findings into practical dosing, combination, readout, and troubleshooting workflows.
-
RBMS1 Loss Enables Immunity in Triple-Negative Breast Cancer
2026-09-17
The reference study identifies RBMS1 as an immune-suppressive RNA-binding protein that maintains PD-L1 stability in immune-cold triple-negative breast cancer through B4GALT1-dependent glycosylation. Its findings connect post-transcriptional RNA control with checkpoint regulation and show why RBMS1 depletion may improve cytotoxic T-cell, checkpoint-blockade, and CAR-T responses in experimental models.